Ipamorelin (2mg*10vials)

Ipamorelin is a synthetic pentapeptide (a chain of five amino acids) classified as a growth hormone secretagogue (GHS) and a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR).

How It Works

• Receptor Activation: It binds to the ghrelin receptor in the pituitary gland and brain, prompting a natural, pulsatile release of growth hormone (GH).

• Selectivity: Unlike older growth hormone-releasing peptides (GHRPs), ipamorelin stimulates GH release without significantly spiking cortisol, prolactin, or appetite levels.

• The CJC-1295 Stack: It is frequently paired with a GHRH (growth hormone-releasing hormone) analog like CJC-1295. While ipamorelin triggers the pulse, CJC-1295 amplifies and extends the signal, producing a larger combined GH response.

Promoted Benefits (Unconfirmed in Controlled Human Trials)

• Increased lean muscle mass and strength

• Enhanced fat loss or reduced visceral fat

• Improved sleep quality and energy levels

• Better post-workout and injury recovery

• Improved skin and tissue regeneration

Administration & Dosage

• Route: Administered via subcutaneous injection (typically using an insulin syringe, often around the abdominal adipose tissue).

• Timing: Commonly injected in a fasted state (such as before bed or post-training) to prevent insulin from blunting the natural GH response.

• Dosing: Typical research or clinical exploration protocols often range between 100–200 mcg per injection.

• Side Effects & Risks: Reported risks include injection-site reactions, fluid retention, tingling/numbness, and alterations in blood glucose or sensitivity. Long-term safety data in humans remains unestablished, and it is contraindicated in individuals with active cancer or uncontrolled endocrine disorders